Abstract
There is an utmost necessity of developing novel biomarkers of depression that result in a more efficacious use of current antidepressant drugs. The present report reviews and discusses a recent series of experiments that focused on analysis of membrane protein clustering in peripheral lymphocytes as putative biomarkers of therapeutic efficacy for major depressive disorder. This review recapitulates how the ideas were originated, and the main findings demonstrated that analysis of serotonin transporter and serotonin 2 A receptor clustering in peripheral lymphocytes of naïve depression patients resulted in a discrimination of two subpopulations of depressed patients that showed a differential response upon 8 weeks of antidepressant treatment. The paper also reviews the usefulness of animal models of depression for an initial evaluation of membrane protein clustering in lymphocytes, which provides a screening tool to determine additional proteins to be further evaluated in depression patients. Finally, the present review provides a brief discussion of the general field of biomarkers of depression in relation to therapeutic outcomes and suggests additional ideas to provide extra value to the reviewed studies.
Highlights
This review recapitulates how the ideas were originated, and the main findings demonstrated that analysis of serotonin transporter and serotonin 2 A receptor clustering in peripheral lymphocytes of naïve depression patients resulted in a discrimination of two subpopulations of depressed patients that showed a differential response upon 8 weeks of antidepressant treatment
Membrane Protein Clustering in Major Depression on biomarkers of depression and on biomarkers of antidepressant response
Logically additional studies on clustering patterns of other membrane proteins would be necessary to prove or falsify that hypothesis, we indicated that patterns of clustering of both serotonin transporter (SERT) and 5HT2A receptor could be considered as putative biomarkers of therapeutic efficacy for major depressive disorder (MDD) (Rivera-Baltanas et al, 2014)
Summary
Non-responders: HDRS scores improvement of less than 25%. Partial responders: HDRS scores improvement between 25 and 50%. Responders without remission: HDRS scores improvement of more than 50%, but absolute value of 7 or more. Remission of symptoms: HDRS scores improvement of more than 50%, and absolute value below 7
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
